Besides, SETD2 is associated with development and progression of several cancers, such as clear cell renal cell carcinoma, breast carcinoma and colorectal cancer, and is involved in chemotherapy resistance in some patients with tumor 7,10-12. Here, SETD2 is linked to breast carcinoma.